Login Register Cart 0
Generic placeholder image

Letters in Drug Design & Discovery

Editor-in-Chief

ISSN (Print): 1570-1808
ISSN (Online): 1875-628X

Back
Research Article

A Comparative Study of Binding Interactions of Natural Flavonoids and Conventional Drug Donepezil for Multiple Alzheimer's Disease Targets Using In silico Approach

Author(s): Devika Sonawane and Varsha Pokharkar*

Volume 20, Issue 12, 2023

Published on: 24 November, 2022

Page: [1947 - 1958] Pages: 12

DOI: 10.2174/1570180819666220509092139

Price: $65

Abstract

Background: Alzheimer's disease (AD) is one of the major causes of morbidity, affecting more than 36 million population worldwide. Current anti-AD treatments result in limited therapeutic outcomes owing to the complexity of the disease. Some natural promising herbal drugs and phytoconstituents utilized as an alternative treatment for AD have been reported by several researchers for their neuroprotective action.

Objective: This study aimed at carrying out molecular docking studies of selected promising flavonoids such as curcumin, quercetin, bilobalide, ferulic acid, reseveratrol for their molecular interactions with multiple AD target proteins and further compare the data with the standard acetylcholine esterase inhibitor drug donepezil.

Methods: The molecular docking interactions were studied between the selected actives and the AD target proteins acetylcholine esterase, butyrylcholine esterase, and tau protein using the AutoDock Vina software. The Swiss ADME approach performed prediction of the ADME properties. Binding interactions of the ligands at the target protein binding sites were examined using the Discovery Studio Visualizer 2021.

Results: The binding energy for quercetin in the active site of the selected target enzymes acetylcholine esterase, butyrylcholine esterase, and tau protein was -9.5 , -7.8 , and -8.2 kcal/mol, respectively which was much greater than other flavonoids and comparable to the standard drug donepezil binding energy - 10.3, -7.5,-7.9 kcal/mol respectively.

Conclusion: This work focuses on recognizing structural features and comparing selected flavonoids and standard acetylcholine esterase (AChEs) inhibitors for molecular docking with three primary targets of AD, namely AChEs, Butyrylcholine esterase, and tau protein. This in silico study concluded that quercetin had significant docking interactions and good pharmacokinetic features, making it a potential therapeutic candidate for the treatment of AD.

Keywords: Alzheimer’s disease, Molecular Docking, Flavonoids, Cholinesterase inhibitors, Donepezil, Quercetin

« Previous Next »
Graphical Abstract

[1]
Tiwari, S.; Venkata, A.; Kaushik, A.; Adriana, Y.; Nair, M. Alzheimer ’ s disease diagnostics and therapeutics market. Int. J. Nanomedicine, 2019, (14), 5541-5554.
[http://dx.doi.org/10.2147/IJN.S200490] [PMID: 31410002]
[2]
Islam, M.R.; Zaman, A.; Jahan, I.; Chakravorty, R.; Chakraborty, S. In silico QSAR analysis of quercetin reveals its potential as therapeutic drug for Alzheimer’s disease. J. Young Pharm., 2013, 5(4), 173-179. [Internet].
[http://dx.doi.org/10.1016/j.jyp.2013.11.005] [PMID: 24563598]
[3]
Grewal, A.S.; Singh, S.; Sharma, N. Grover. In silico docking studies of some flavonoids against multiple targets of Alzheimer’s disease. Plant Arch., 2020, 20, 3271-3278.
[4]
Swerdlow, RH Pathogenesis of Alzheimer’s disease. 2007, 2(3), 347-359.
[5]
Ivanova, L.; Karelson, M.; Dobchev, D.A. Identification of natural compounds against neurodegenerative diseases using in silico techniques. Molecules, 2018, 23(8), E1847.
[http://dx.doi.org/10.3390/molecules23081847] [PMID: 30044400]
[6]
Association, A Alzheimer’s Association. FDA-approved treatments for Alzheimer’s., 2019, 1-5.
[7]
Somani, G.; Kulkarni, C.; Shinde, P.; Shelke, R.; Laddha, K.; Sathaye, S. In vitro acetylcholinesterase inhibition by psoralen using molecular docking and enzymatic studies. J. Pharm. Bioallied Sci., 2015, 7(1), 32-36.
[http://dx.doi.org/10.4103/0975-7406.148775] [PMID: 25709334]
[8]
Chen, BW; Li, WX; Wang, GH; Li, GH; Liu, JQ; Zheng, JJ A strategy to find novel candidate anti-Alzheimer’s disease drugs by constructing interaction networks between drug targets and natural compounds in medical plants. PeerJ, 2018, 2018.
[http://dx.doi.org/10.7717/peerj.4756]
[9]
Naoi, M.; Shamoto-Nagai, M.; Maruyama, W. Neuroprotection of multifunctional phytochemicals as novel therapeutic strategy for neurodegenerative disorders: Antiapoptotic and antiamyloidogenic activities by modulation of cellular signal pathways. Future Neurol., 2019, 14(1)
[http://dx.doi.org/10.2217/fnl-2018-0028]
[10]
Scotti, L.; Mendonca, Junior, F.J.; Ishiki, H.M.; Ribeiro, F.F.; Singla, R.K.; Barbosa Filho, J.M.; Da Silva, M.S.; Scotti, M.T. Docking studies for multi-target drugs. Curr. Drug Targets, 2017, 18(5), 592-604.
[http://dx.doi.org/10.2174/1389450116666150825111818] [PMID: 26302806]
[11]
Picot-Allain, C.M.N.; Mahomoodally, F.M. Neuroprotective potential of phytochemicals viain silico molecular docking techniques [Internet]. Studies in natural products chemistry.Elsevier Inc, 1st ed;; , 2019, 63, pp. 243-266.
[http://dx.doi.org/10.1016/B978-0-12-817901-7.00009-5]
[12]
Cheung, J.; Rudolph, M.J.; Burshteyn, F.; Cassidy, M.S.; Gary, E.N.; Love, J.; Franklin, M.C.; Height, J.J. Structures of human acetylcholinesterase in complex with pharmacologically important ligands. J. Med. Chem., 2012, 55(22), 10282-10286.
[http://dx.doi.org/10.1021/jm300871x] [PMID: 23035744]
[13]
Brus, B.; Košak, U.; Turk, S.; Pišlar, A.; Coquelle, N.; Kos, J.; Stojan, J.; Colletier, J.P.; Gobec, S. Discovery, biological evaluation, and crystal structure of a novel nanomolar selective butyrylcholinesterase inhibitor. J. Med. Chem., 2014, 57(19), 8167-8179.
[http://dx.doi.org/10.1021/jm501195e] [PMID: 25226236]
[14]
Aoki, M.; Yokota, T.; Sugiura, I.; Sasaki, C.; Hasegawa, T.; Okumura, C.; Ishiguro, K.; Kohno, T.; Sugio, S.; Matsuzaki, T. Structural insight into nucleotide recognition in tau-protein kinase I/glycogen synthase kinase 3 β. Acta Crystallogr. D Biol. Crystallogr., 2004, 60(Pt 3), 439-446.
[http://dx.doi.org/10.1107/S090744490302938X] [PMID: 14993667]
[15]
PubChem [Internet]. Bethesda (MD): National library of medicine (US), national center for biotechnology information; PubChem Compound Summary for CID 3152, Donepezil, 2004. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Donepezil
[16]
PubChem [Internet]. Bethesda (MD): National Library of Medicine(US), National Center for Biotechnology Information; 2004-. Pub-Chem Compound Summary for CID 5280343, Quercetin; [cited 2022 Mar. 20]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Quercetin
[17]
PubChem [Internet]. Bethesda (MD): National library of medicine (US), national center for biotechnology information; PubChem Compound Summary for CID 969516, Curcumin, 2004. Available from:: https://pubchem.ncbi.nlm.nih.gov/compound/Curcumin
[18]
PubChem [Internet]. Bethesda (MD): National library of medicine (US), national center for biotechnology information; PubChem Compound Summary for CID 445858, Ferulic acid, 2004. Available from:: https://pubchem.ncbi.nlm.nih.gov/compound/Ferulic-acid
[19]
PubChem [Internet]. Bethesda (MD): National library of medicine (US), national center for biotechnology information; PubChem Compound Summary for CID 73581, Bilobalide, 2004. Available from:: https://pubchem.ncbi.nlm.nih.gov/compound/Bilobalide
[20]
PubChem [Internet]. Bethesda (MD): National library of medicine (US), national center for biotechnology information; PubChem Compound Summary for CID 445154, Resveratrol, 2004. Available from:: https://pubchem.ncbi.nlm.nih.gov/compound/Resveratrol
[21]
Vistoli, G.; Pedretti, A.; Testa, B. Assessing drug-likeness--what are we missing? Drug Discov. Today, 2008, 13(7-8), 285-294.
[http://dx.doi.org/10.1016/j.drudis.2007.11.007] [PMID: 18405840]
[22]
Walters, W.P.; Murcko, M.A. Prediction of ‘drug-likeness’. Adv. Drug Deliv. Rev., 2002, 54(3), 255-271.
[http://dx.doi.org/10.1016/S0169-409X(02)00003-0] [PMID: 11922947]
[23]
Meng, X.Y.; Zhang, H.X.; Mezei, M.; Cui, M.; Meng, X.Y.; Zhang, H.X.; Mezei, M.; Cui, M. Molecular docking: A powerful approach for structure-based drug discovery. Curr. Computeraided Drug Des., 2011, 7(2), 146-157.
[http://dx.doi.org/10.2174/157340911795677602] [PMID: 21534921]
[24]
Perola, E.; Walters, W.P.; Charifson, P.S. A detailed comparison of current docking and scoring methods on systems of pharmaceutical relevance. Proteins, 2004, 56(2), 235-249.
[http://dx.doi.org/10.1002/prot.20088] [PMID: 15211508]
[25]
Daina, A.; Michielin, O.; Zoete, V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep., 2016, 2017(7), 1-13.
[PMID: 28256516]

Rights & Permissions Print Cite
Article Metrics
1
© 2024 Bentham Science Publishers | Privacy Policy